KaliVir Immunotherapeutics
Pittsburgh
About KaliVir Immunotherapeutics
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2022)
- Website: kalivir.com
- Phone: +1 412 435 6730
Industries & Categories
Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kalivir-immunotherapeutics-2238443 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.